QurAlis News and Activities

QurAlis is owned by Mission BioCapital. Mission BioCapital has a direct presence in 2 countries.

Mission BioCapital has 20 subsidiaries including Alessa Therapeutics, Avvio Medical and Avvio Medical AMEA.

They are in:

• Biotechnology76%
• Healthcare10%
• Other14%

Acquisition, funding and merger involving Mission BioCapital.

• Mission BioCapital has just announced a $134 Million fundraising (posted on September 28 2025).

View the org chart displaying its 19 main executives

Most searched biographies at QurAlis

• Kasper Roet, Chief Executive Officer and Director
• Luc Dochez, Director
• Laia Crespo, Director

Popular executive movements at QurAlis

• Manoj Malhotra has joined the company as Chief Medical Officer  (posted on November 11 2025).

Create your alert
to follow the executive moves at QurAlis.

Mission BioCapital has 2,415 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Vertex Pharmaceuticals (United States (USA)).

Popular M&A news in Biotechnology

• RQ Biotechnology has just announced a $86 Million fundraising (posted on June 24 2026).
• Boundless Bio has filed its IPO. Its stock ticker will be AATD. (posted on June 23 2026).
• Boundless Bio will change its company name to Serapha Bio on Dec 31, 2026. (posted on June 23 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Carl Gordon - Director at Odyssey Therapeutics
• Jan Van de Winkel - President and Chief Executive Officer at Genmab

Learn more about the Biotechnology industry

Press releases by QurAlis

• QurAlis Demonstrates Effects on Disease Progression and Target Engagement in ANQUR Clinical Trial of QRL-201, a First-in-Class Precision Medicine in Development for Sporadic ALS - QurAlis
• QurAlis Confirms Signal of Target Engagement in ALS Patients in Phase 1 Clinical Trial of QRL-101, a Potentially Best-in-Class Selective Kv7.2/7.3 Ion Channel Opener - QurAlis
• QurAlis Invited to Present at 44th Annual J.P. Morgan Healthcare Conference - QurAlis
• QurAlis to Present Data From its Phase 1 Clinical Trial of QRL-101, a Potential Best-in-Class Selective Kv7.2/7.3 Ion Channel Opener, at American Epilepsy Society 2025 Annual Meeting - QurAlis
• QurAlis to Participate in Piper Sandler 37th Annual Healthcare Conference - QurAlis
• QurAlis Announces Appointment of Manoj Malhotra, M.D., as Chief Medical Officer - QurAlis
• QurAlis to Participate in Upcoming Investor Conferences in November - QurAlis
• QurAlis to Participate in Upcoming Investor Conferences in September - QurAlis
• ­­­QurAlis Announces New Global Headquarters - QurAlis
• Quiver Bioscience and QurAlis Announce Research Collaboration to Advance Novel Therapeutic Approach for Fragile X Syndrome - QurAlis
• View more press releases Close

Social media about QurAlis

• QurAlis on Wikipedia, Google News & Yahoo Finance
• QurAlis on LinkedIn, X (Twitter) & YouTube